Evaluating Blue Zones Demography in Response to Recent Critiques
January 6, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
tymlos
Synonyms :
abaloparatide
Class :
Parathyroid hormone analogue
Brand Name :
tymlos
Synonyms :
abaloparatide
Class :
Parathyroid hormone analogue
Dosage Forms & Strengths
Subcutaneous injection
80mcg/40mcl
Men
80mcg subcutaneous everyday
Postmenopausal women
80mcg subcutaneous everyday
Dosage Forms & Strengths
Safety and efficacy not established
Refer adult dosing
may have an increased hypoglycemic effect when combined with meglitinides
may have an increased hypoglycemic effect when combined with meglitinides
It may decrease the effects of human parathyroid hormone
It may decrease the effects of human parathyroid hormone
It may decrease the effects of human parathyroid hormone
It may decrease the effects of human parathyroid hormone
It may decrease the effects of human parathyroid hormone
It may decrease the effects of human parathyroid hormone
When levobupivacaine and abaloparatide are combined, the risk or seriousness of adverse events will rise
It may enhance the risk of adverse effects when combined with Peptide Hormones
It may enhance the risk of adverse effects when combined with Peptide Hormones
It may enhance the risk of adverse effects when combined with Peptide Hormones
It may enhance the risk of adverse effects when combined with Peptide Hormones
It may enhance the risk of adverse effects when combined with Peptide Hormones
It may enhance the risk of adverse effects when combined with biologic agents
It may enhance the risk of adverse effects when combined with biologic agents
It may enhance the risk of adverse effects when combined with biologic agents
It may enhance the risk of adverse effects when combined with biologic agents
It may enhance the risk of adverse effects when combined with biologic agents
It may enhance the risk of adverse effects when combined with peptide analogs
It may enhance the risk of adverse effects when combined with peptide analogs
It may enhance the risk of adverse effects when combined with calcium
It may enhance the risk of adverse effects when combined with calcium
It may enhance the risk of adverse effects when combined with calcium
It may enhance the risk of adverse effects when combined with calcium
It may enhance the risk of adverse effects when combined with calcium
the hypotensive activities of muzolimine may be increased when used in conjunction with abaloparatide
abaloparatide: it may increase the risk of adverse effects of oxprenolol
may increase the hypoglycemic effect of direct-acting viral agents
may increase the hypoglycemic effect of direct-acting antiviral agents
may enhance the hypoglycemic effect of beta blockers
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the hypoglycemic effect of salicylates
may increase the hypoglycemic effect of hypoglycemia-associated agents
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
relugolix/estradiol/norethindrone
may enhance the hypoglycemic effect
relugolix/estradiol/norethindrone
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
the risk of hypotensive activity of Remikiren may be increased
the hypotensive activity of candoxatril may be increased
the risk or extent of hypotension can be increased when fostamatinib is combined with abaloparatide
the risk of adverse effects may be increased
Frequency defined:
>10%
Men
Erythema injection site
Women
Hypercalciuria
Redness at the injection site
Edema at the injection site
1-10%
Men
Arthralgia
Increased serum uric acid
Pain at the injection site
Contusion
Nausea
Abdominal pain
Post-marketing reports
Pregnancy consideration: Not recommended for women with reproductive potential
Lactation: Not recommended for women with reproductive potential
Pregnancy category:
pharmacology:
Abaloparatide activates the parathyroid hormone receptor type 1 and triggers anabolic responses in osteoblasts by stimulating the Gs-protein mediated cyclic adenosine monophosphate (cAMP) pathway. This activation initiates phospholipase C and phosphokinase A promoting increased osteoblast activity.
Pharmacodynamics:
Abaloparatide alters bone remodeling balance that leading to enhanced bone formation at periosteal, trabecular, and endocortical surfaces.
Binding to the R0 conformation results in a prolonged signaling response with a gradual increase in cAMP levels but increases the risk of hypercalcemia due to elevated osteoclast activity. It’s binding capacity to the RG conformation was assessed through radioligand competition methods indicating its anabolic effects.
pharmacokinetics:
Absorption
In healthy women administering 80 mcg of the drug results in an absolute bioavailability of 36%.
Distribution
It has a distribution volume of approximately 50 L and approximately 70% plasma protein binding.
Metabolism:
Its peptide fragments are primarily excreted in the kidneys after nonspecific proteolytic degradation.
Excretion:
The half-life is approximately 1 hour it is primarily eliminated through renal excretion. However, close monitoring is necessary for adverse reactions in severe cases.
The recommended adult dosage for managing osteoporosis in postmenopausal women is 80 mcg subcutaneously once daily. If dietary intake is insufficient then calcium and vitamin D should be supplemented. This drug reduces the vertebral and nonvertebral fractures in postmenopausal women with osteoporosis that is characterized by a history of osteoporotic fracture, multiple fracture risk factors, and inability to tolerate other treatments.
Patient information leaflet
Generic Name: abaloparatide
Why do we use abaloparatide?
Abaloparatide is a synthetic peptide analog of PTHrP which is used to manage osteoporosis characterized by reduced bone mineral density and altered bone structure by increasing fracture risk. FDA approved its use in postmenopausal women and men with similar risk and for those who cannot tolerate or have proven ineffective treatments for alternative osteoporosis treatments.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
